Home | Welcome to Contract Pharma   
Last Updated Saturday, September 20 2014
Print

Quotient Clinical Extends Translational Pharmaceutics Platform



Published April 24, 2014
Related Searches: Development Manufacturing Testing
Quotient Clinical has extended its Translational Pharmaceutics platform into cancer drug development, employing its real-time manufacturing capabilities to supply drug products to support first-in-patient and proof-of-concept programs.
 
Translational Pharmaceutics integrates real-time drug product manufacturing and clinical testing, using processes designed to reduce the timelines and cost of early stage drug development. Quotient has applied this platform in early development programs at its own manufacturing and clinical facilities in Nottingham, UK.
 
Quotient’s real-time manufacturing approach offers a number of advantages in this setting, including:flexibility of drug product manufacturing in response to patient recruitment rates, with product typically being supplied in less than three weeks,customization of drug product dose and/or composition according to patient/study need, and in response to clinical data emerging from the on-going program;and increased efficiency of drug substance consumption.
 
Mark Egerton, chief executive officer of Quotient Clinical, said, “Approximately 30% of the industry’s drug development pipeline is focused on cancer. We have developed our real-time manufacturing and supply capabilities to support this specialist area with first-in-patient and proof-of-concept programs. We have already supported multiple development programs in the UK and mainland Europe, and will shortly be embarking on a similar project in North America. In these, and other future programs, we will be helping our clients to accelerate their early development pipelines and increase overall R&D productivity.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On